Cargando…

Polη O-GlcNAcylation governs genome integrity during translesion DNA synthesis

DNA polymerase η (Polη) facilitates translesion DNA synthesis (TLS) across ultraviolet (UV) irradiation- and cisplatin-induced DNA lesions implicated in skin carcinogenesis and chemoresistant phenotype formation, respectively. However, whether post-translational modifications of Polη are involved in...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Xiaolu, Liu, Hongmei, Li, Jing, Wang, Yihao, Ding, Yue-He, Shen, Hongyan, Yang, Yeran, Sun, Chenyi, Huang, Min, Tu, Yingfeng, Liu, Yang, Zhao, Yongliang, Dong, Meng-Qiu, Xu, Ping, Tang, Tie-Shan, Guo, Caixia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5717138/
https://www.ncbi.nlm.nih.gov/pubmed/29208956
http://dx.doi.org/10.1038/s41467-017-02164-1
Descripción
Sumario:DNA polymerase η (Polη) facilitates translesion DNA synthesis (TLS) across ultraviolet (UV) irradiation- and cisplatin-induced DNA lesions implicated in skin carcinogenesis and chemoresistant phenotype formation, respectively. However, whether post-translational modifications of Polη are involved in these processes remains largely unknown. Here, we reported that human Polη undergoes O-GlcNAcylation at threonine 457 by O-GlcNAc transferase upon DNA damage. Abrogation of this modification results in a reduced level of CRL4(CDT2)-dependent Polη polyubiquitination at lysine 462, a delayed p97-dependent removal of Polη from replication forks, and significantly enhanced UV-induced mutagenesis even though Polη focus formation and its efficacy to bypass across cyclobutane pyrimidine dimers after UV irradiation are not affected. Furthermore, the O-GlcNAc-deficient T457A mutation impairs TLS to bypass across cisplatin-induced lesions, causing increased cellular sensitivity to cisplatin. Our findings demonstrate a novel role of Polη O-GlcNAcylation in TLS regulation and genome stability maintenance and establish a new rationale to improve chemotherapeutic treatment.